Poor outcome of patients with COVID-19 after CAR T Cell therapy for B-cell malignancies: results from a multicenter study on behalf of the european society for blood and marrow transplantation (EBMT) infectious diseases working party and the European Hematology Association (EHA) Lymphoma Group
Authors
Spanjaart, A. M.Ljungman, P.
De La Camara, R.
Tridello, G.
Ortiz-Maldonado, V.
Urbano-Ispizua, A.
Barba, P.
Kwon, M.
Caballero, D.
Sesques, P.
Bachy, E.
Di Blasi, R.
Thieblemont, C.
Calkoen, F.
Mutsaers, P.
Maertens, J. A.
Giannoni, L.
Nicholson, E.
Collin, M. P.
Vaz, C. P.
Metafuni, E.
Martinez-Lopez, J.
Dignan, F.
Ribera, J. M.
Nagler, A.
Folber, F.
Sanderson, R.
Bloor, Adrian
Ciceri, F.
Knelange, N.
Ayuk, F. A.
Kroger, N.
Kersten, M. J.
Mielke, S.
Affiliation
Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam and LYMMCARE, AmsterdamIssue Date
2021
Metadata
Show full item recordCitation
Spanjaart AM, Ljungman P, De La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor Outcome of Patients with COVID-19 after CAR TCell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413903112.Journal
BloodDOI
10.1182/blood-2021-149466Additional Links
https://dx.doi.org/10.1182/blood-2021-149466Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-149466